9th Nov 2009 18:04
|
For immediate release |
9 November 2009 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Dealings: LTIP
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that on 9 November 2009 the Remuneration Committee granted the following conditional nil cost share awards at a price of 904 pence per ordinary share (the closing share price on 6 November 2009) to the Executive Directors of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):
|
Name |
Number of Ordinary Shares subject to the LTIP Award |
|
Jonathan Milner |
27,399 |
|
Jim Warwick |
24,744 |
|
Jeff Iliffe |
23,416 |
The shares subject to the LTIP awards issued to Executive Directors will be released in three years' time subject to continued employment and subject to the satisfaction of certain specific performance conditions based on:
In addition, the following PDMRs were also granted LTIP awards in accordance with the rules of the LTIP:
|
Name |
Number of Ordinary Shares subject to the LTIP Award |
|
Mark Bushfield |
8,151 |
|
Jane Cooke |
2,895 |
|
Philippe Cotrel |
8,151 |
The shares subject to the LTIP awards issued to PDMRs will vest in three years' time subject to the achievement of specific performance criteria.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
Related Shares:
ABC.L